
BHVN Stock Forecast & Price Target
BHVN Analyst Ratings
Bulls say
Biohaven is viewed positively because its broad, science-driven pipeline spans high-value areas such as neuroscience, immunology, and oncology, creating multiple shots on goal with differentiated assets like BHV-7000 and the degrader platform. The FDA’s acceptance of the troriluzole filing with a 1Q27 PDUFA and Adcomm is a major near-term catalyst, with the opportunity modeled at about $1.2B to $1.24B and a 40% probability of success, while approval could materially transform the company into a commercial rare-disease story. Longer term, the company’s capital efficiency may improve from the $350M upfront and $50M next year, royalty economics, and reduced burn, supporting a more focused business with meaningful optionality if late-stage readouts are successful.
Bears say
Biohaven is viewed negatively because its value depends on a long-dated, high-risk pipeline while several key programs face regulatory and clinical uncertainty, including the FDA’s partial clinical hold on opakalim and unresolved questions around troriluzole in SCA. The hold delays enrollment and the second-half of 2026 readout for BHV-7000-303, widening a competitive gap versus Xenon while also threatening the timing and economics of the $400M upfront SK deal plus up to $150M in milestones and royalties. At the same time, the company’s broad multi-asset strategy increases R&D and SG&A spend, and the lack of direct clinical data across some phase III programs leaves the stock more exposed to disappointing readouts and regulatory setbacks.
This aggregate rating is based on analysts' research of Biohaven Pharmaceutical Hld and is not a guaranteed prediction by Public.com or investment advice.
BHVN Analyst Forecast & Price Prediction
Start investing in BHVN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Biohaven Pharmaceutical Hld (BHVN) Forecast
BHVN Analyst Forecast & Price Prediction
Start investing in BHVN
Order type
Buy in
Order amount
Est. shares
0 shares